Lamotrigine as an add-on treatment for depersonalization disorder: A retrospective study of 32 cases

Clinical Neuropharmacology

Volumn 29, Issue 5, 2006, Pages 253-258

  Sierra, Mauricio ^a   Baker, Dawn ^a   Medford, Nicholas ^a   Lawrence, Emma ^a   Patel, Maxine ^a   Phillips, Mary L ^a   David, Anthony S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CDS; Depersonalization; Depression; Derealization; Dissociation; Glutamate; Lamotrigine; Selective serotonin reuptake inhibitor

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; LAMOTRIGINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CAMBRIDGE DEPERSONALIZATION SCALE; CHRONIC DISEASE; CLINICAL ARTICLE; DEPERSONALIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; FOLLOW UP; HUMAN; MALE; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; COHORT STUDIES; DEPERSONALIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TRIAZINES;

EID: 33748958509     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000228368.17970.DA     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, 4th ed. Washington, DC: American Psychiatric Press; 1994.
2. The ICD-10 classification of mental and behavioural disorders, 10th ed. Geneva: World Health Organization; 1992.
3. Simeon D, Knutelska M, Nelson D, et al. Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry 2003;64:990-997.
4. Baker D, Hunter E, Lawrence E, et al. Depersonalization disorder: clinical features of 204 cases. Br J Psychiatry 2003;182:428-433.
5. Hunter ECM, Sierra M, David AS. The epidemiology of depersonalization and derealization: a systematic review. Soc Psychiatry Psychiatr Epidemiol 2004;39:9-18.
6. Ross CA. Epidemiology of multiple personality disorder and dissociation. Psychiatr Clin N Am 1991;14:503-517.
7. Aderibigbe YA, Bloch RM, Walker WR. Prevalence of depersonalization and derealization experiences in a rural population. Soc Psychiatry Psychiatr Epidemiol 2001;36:63-69.
8. Brauer R, Harrow M, Tucker GJ. Depersonalization phenomena in psychiatric patients. Br J Psychiatry 1970;117:509-515.
9. Noyes R, Hoenk PR, Kuperman S, et al. Depersonalization in accident victims and psychiatric patients. J Nerv Ment Dis 1977;164:401-407.
10. Shorvon HJ, Hill JDN, Burkitt E. The depersonalization syndrome. Proc R Soc Med 1946;39:779-792.
11. Ackner B. Depersonalization - I. aetiology and phenomenology; II. clinical syndromes. J Ment Sci 1954;100:838-872.
12. Hollander E, Liebowitz MR, DeCaria C, et al. Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol 1990;10:200-203.
13. Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine. Biol Psychiatry 1998;44:302-303.
14. Simeon D, Guralnik O, Schmeidler J, et al. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry 2004;185:31-36.
15. Simeon D, Hollander E, Stein DJ, et al. Induction of depersonalization by serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res 1995;58:161-164.
16. Medford N, Baker D, Hunter E, et al. Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases. Addiction 2003;98:1731-1736.
17. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with methylenedioxymethamphetamine ('ecstasy'). Br J Psychiatry 1994;165:391-395.
18. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
19. Abel KM, Allin MP, Kucharska-Pietura K, et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003;14:387-391.
20. Abel KM, Allin MP, Kucharska-Pietura K, et al. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive State. Hum Brain Mapp 2003;18:135-145.
21. Phillips ML, Medford N, Senior C, et al. Depersonalization disorder: thinking without feeling. Psychiatry Research: Neuroimaging 2001;108:145-160.
22. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-307.
23. Wang SJ, Huang CC, Hsu KS, et al. Presynaptic inhibition of excitatory neurotransmision by lamotrigine in the rat amygdalar neurons. Synapse 1996;24:248-255.
24. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000;57:270-276.
25. Sierra M, Phillips ML, Lambert MV, et al. Lamotrigine in the treatment of depersonalization disorder. J Clin Psychiatry 2001;62:826-827.
26. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998;38:119-130.
27. Sierra M, Phillips ML, Ivin G, et al. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol 2003;17:103-105.
28. Wing JK, Cooper JE, Sartorius NT. The Description and Classification of Psychiatric Symptoms: An Instruction Manual for the PSE and CATEGO Program. Cambridge, UK: Cambridge University Press; 1994.
29. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988a;56:893-897.
30. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988b;8:77-100.
31. Carlson EB, Putnam FW. An update on the Dissociative Experiences Scale. Dissociation 1993;6:16-27.
32. Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res 2000;93:153-164.
33. Normann C, Hummel B, Scharer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002;63:337-344.
34. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45:1226-1229.
35. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51:333-343.
36. Sanacora G, Rothman DL, Mason G, et al. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann NY Acad Sci 2003;1003:292-308.
37. Sanacora G, Mason GF, Rothman DL, et al. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002;159:663-665.